Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : PYNG Technologies -- Ignore unavailable to you. Want to Upgrade?

To: Justin Curran who wrote (960)	3/16/1998 6:05:00 PM
From: Mr Metals	Read Replies (1) \| Respond to of 8117

After reading this, I think she might soar. Pyng Technologies Corp - F.A.S.T. 1 Tops FDA's "Significant Medical Breakthroughs 1997" List Pyng Technologies Corp PYT Shares issued 7677856 1998-03-13 close $5.85 Monday Mar 16 1998 F.A.S.T.1 TOPS FDA'S "SIGNIFICANT MEDICAL BREAKTHROUGHS 1997" LIST March 16, 1998 Michael W. Jacobs, President of Pyng Technologies Corp. (the "Company") is pleased to announce that the F.A.S.T. 1 Adult Intraosseous Infusion System has received formal recognition from the FDA's Office of Device Evaluation ("ODE") in their annual report for the fiscal year 1997 as a significant medical breakthrough. Thirty-five devices have been recognized by the ODE in several categories out of 20,000 submissions received and reviewed. The ODE recognizes these devices, including the F.A.S.T. 1 as "significant medical breakthroughs because they are first-of-a-kind, e.g. they use a new technology or energy source, or they provide a major diagnostic or therapeutic advancement, such as reducing hospital stays, replacing the need for surgical intervention, and reducing the time needed for diagnostic determination." The FAST 1 is the world's first adult intraosseous infusion system approved by the US FDA. Pyng Medical Corporation has just been advised by the FDA Office of Device Evaluation that their Annual Report is available on the Internet at the FDA website. (www.fda.gov/cdrh). FIRST USE OF F.A.S.T. 1 INTRAOSSEOUS INFUSION SYSTEM IN A CONSCIOUS HUMAN SUBJECT March 13, 1998 Pyng Technologies Corp. is pleased to announce that the F.A.S.T. 1 Intraosseous Infusion System produced by its subsidiary, Pyng Medical Corp., has been successfully used on a conscious, live human subject. The F.A.S.T. 1 was designed to achieve fast, reliable vascular access under emergency conditions in the pre-hospital environment. Pyng Medical recently completed training of emergency physicians at University of Maryland Medical Centre. Following the training, Dr. Tom Stair, Research Director, The University or Maryland School of Medicine, decided he wanted to know what the F.A.S.T. 1 would feel like, and volunteered to have it used on him. Dr. Stair and a colleague developed a fast (60 secconds) procedure for anaesthetising the skin over the sternal insertion site. This procedure is suitable for use by some paramedics. Using this freezing procedure, the F.A.S.T. 1 system was used on Dr. Stair. Fluids were rapidly infused into him. He experienced no pain. In fact, Dr. Stair reported that the procedure caused less pain than giving blood. Daily follow-ups for the three days following the procedure showed no medical complications. Thanks to the leadership of Dr. Stair and colleagues, Pyng Medical has demonstrated that within 2.5 minutes or less, a paramedic can reliably and simply achieve vascular access in a conscious patient. This discovery means market penetration will likely be greater and faster than is predicted in our financial projections. More news releases will follow as other ambulance services, paramedics, and emergency hospitals adopt and begin to use the F.A.S.T. 1 system. CLARIFICATION OF RUMOURS OF CONCERN TO THE VANCOUVER STOCK EXCHANGE March 16, 1998 Michael Jacobs, President of Pyng Technologies Corp. (the "Company"), wishes to address several media rumours concerning the Company and the F.A.S.T. 1 System. These rumours have been brought to the Company's attention by the Vancouver Stock Exchange. Firstly, it has been rumoured that the F.A.S.T. 1 system will be "featured" on an undetermined NBC Television Program. This rumour has been circulating on the Internet and the Company has no knowledge either of its source or its truthfulness. Secondly, a rumour concerning a feature article to appear in Bloomberg is apparently also circulating. Mr. Jacobs was interviewed by the Bloomberg news service in late February. Any publication concerning this interview by Bloomberg is not a matter within the control of the Company. FOR FURTHER INFORMATION, PLEASE CONTACT: Michael W. Jacobs 1(800) 349-7964 or at the Lab (604) 875-4526 e-mail: pyngmed@axionet.com website: pyng.com The VSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. (c) Copyright 1997 Canjex Publishing Ltd. canada-stockwatch.com Mr Metals